Design Therapeutics (DSGN) insider buying

Healthcare · Biotechnology · Market cap $669M

4 open-market purchases of DSGN by Design Therapeutics's executives and directors since August 2023, worth $176,820 in total, from SEC Form 4 filings.

The most recent: John P Schmid bought $66,606 on March 25, 2024.

The biggest buyer over the period is John P Schmid: 2 purchases, $99,750.

By year

YearPurchasesValue
20242$99,750
20232$77,070

Biggest buyers

InsiderBuysValue
John P Schmid
2$99,750
Rodney W Lappe
1$49,350
Deepa Prasad
1$27,720

Every purchase

Newest first. From SEC Form 4 filings. Insider buying across the market.

DateInsiderSharesPriceValueFiling
Mar 25, 2024 John P Schmid
 17,809$3.74$66,606 Form 4
Mar 22, 2024 John P Schmid
 9,156$3.62$33,145 Form 4
Sep 29, 2023 Rodney W Lappe
 21,000$2.35$49,350 Form 4
Aug 29, 2023 Deepa Prasad
 12,000$2.31$27,720 Form 4
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for DSGN.
Open DSGN in Investingly

Questions

Are Design Therapeutics insiders buying the stock?

4 open-market purchases of DSGN by Design Therapeutics's executives and directors since August 2023, worth $176,820 in total, from SEC Form 4 filings. The most recent: John P Schmid bought $66,606 on March 25, 2024.

What counts as insider buying here?

Open-market purchases (Form 4 code P) by officers and directors. Option exercises, grants and purchases by 10% owners are left out.

From Design Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.